SIRT1 and miR-34a-5p Expression in Peripheral Blood Mononuclear Cells (PBMCs) as Potential Biomarkers for Patients With Type 2 Diabetes With Cognitive Impairments
Authors' conclusion
Our findings revealed that there was an alteration of mitochondria at the peripheral level in patients with T2DM-CI. SIRT1 combined with miR-34a-5p in PBMCs performed well in identifying patients with T2DM-CI and may be a promising biomarker.
Study context
- Population
- Patients with Alzheimer disease (AD), T2D with or without cognitive impairment, and healthy controls
- Participants
- 374 patients
- Comparison
- AD, T2D-CI, T2D-nCI and healthy controls
- Outcome
- Discrimination of T2DM-CI vs T2DM-nCI by SIRT1 plus miR-34a-5p in PBMCs
Performance
As reported in the abstract
| Test or model | AUC | Sensitivity | Specificity |
|---|---|---|---|
| SIRT1 + miR-34a-5p | 0.793 | 80.01% | 78.46% |
SIRT1 + miR-34a-5p
AUC0.793
Sensitivity80.01%
Specificity78.46%
- Mitochondrial DNA (mtDNA) content and SIRT1 mRNA lower, miR-34a-5p higher in T2DM with cognitive impairment (T2DM-CI) vs T2DM-nCI
- all P < .05
Further findings
Mitochondrial function in PBMCs
- Significant changes in AD vs controls, not found in T2DM-CI
- all P < .05
Correlation of miR-34a-5p with hyperglycaemia
- Link between miR-34a-5p expression and hyperglycemia in T2DM-CI
Original publication
SIRT1 and miR-34a-5p Expression in PBMCs as Potential Biomarkers for Patients With Type 2 Diabetes With Cognitive Impairments. J Clin Endocrinol Metab. Published 27 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →